| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenues | 3,982 | 4,704* | 4,480 | NaN |
| Cost of sales | 2,011 | 2,035* | 2,176 | NaN |
| Gross profit | 1,972 | 2,669* | 2,304 | NaN |
| Research and development expenses | 222 | 259* | 256 | NaN |
| Selling and marketing expenses | 696 | 769* | 656 | NaN |
| General and administrative expenses | 304 | 366* | 317 | NaN |
| Intangible assets impairments | 8 | -18* | 64 | NaN |
| Goodwill impairment | NaN | 0* | 0 | NaN |
| Other assets impairments, restructuring and other items | 26 | 990* | 62 | NaN |
| Legal settlements and loss contingencies | 72 | 248* | 60 | NaN |
| Other loss (income) | 9 | 0* | -7 | NaN |
| Operating income (loss) | 652 | 56* | 882 | NaN |
| Financial expenses, net | -216 | -242* | -237 | NaN |
| Income (gain) before income taxes | 437 | -187* | 646 | NaN |
| Adjustments to valuation allowances on deferred tax assets-Revenue Commissioners Ireland | NaN | 10* | NaN | NaN |
| Other (amount)-Revenue Commissioners Ireland | NaN | -1* | NaN | NaN |
| Statutory tax rate difference (amount)-Malta Tax Authority | NaN | 9* | NaN | NaN |
| Reduced rate due to imputation system (amount)-Malta Tax Authority | NaN | 22* | NaN | NaN |
| Other (amount)-Malta Tax Authority | NaN | 2* | NaN | NaN |
| Adjustments to valuation allowances on deferred tax assets-Tax And Customs Administration Netherlands | NaN | 35* | NaN | NaN |
| Other (amount)-Tax And Customs Administration Netherlands | NaN | -0* | NaN | NaN |
| Statutory tax rate difference (amount)-Swiss Federal Tax Administration FTA | NaN | -40* | NaN | NaN |
| Adjustments to valuation allowances on deferred tax assets-Swiss Federal Tax Administration FTA | NaN | -8* | NaN | NaN |
| Other (amount)-Swiss Federal Tax Administration FTA | NaN | 1* | NaN | NaN |
| Changes in unrecognized tax benefits (amount)-Other Countries Tax Authority | NaN | 15* | NaN | NaN |
| Adjustments to valuation allowances on deferred tax assets-Other Countries Tax Authority | NaN | 661* | NaN | NaN |
| Income taxes (benefit) | 67 | -659* | 214 | NaN |
| Share in (profits) losses of associated companies net | -1 | 9* | 2 | NaN |
| Net income (loss) | 369 | 481 | 434 | 283 |
| Net income (gain) attributable to redeemable and non-redeemable non-controlling interests | NaN | 0 | 1 | NaN |
| Net income (loss) attributable to teva | 369 | 481 | 433 | 282 |
| Basic EPS | 0.32 | 0.419 | 0.38 | 0.25 |
| Diluted EPS | 0.31 | 0.412 | 0.37 | 0.24 |
| Basic Average Shares | 1,156,000,000 | 1,148,000,000 | 1,147,000,000 | 1,147,000,000 |
| Diluted Average Shares | 1,179,000,000 | 1,168,000,000 | 1,164,000,000 | 1,161,000,000 |
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF)
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF)